resveratrol has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY | 1 |
| Bennett, LL; Mondal, A | 1 |
| Gao, W; Luo, C; Ma, L; Man, S; Yan, M; Zhao, G | 1 |
1 review(s) available for resveratrol and sorafenib
| Article | Year |
|---|---|
Treatment for liver cancer: From sorafenib to natural products.
Topics: Antineoplastic Agents; Biological Products; Flavonoids; Ginsenosides; Humans; Immediate-Early Proteins; Liver Neoplasms; Neoplastic Stem Cells; Protein Serine-Threonine Kinases; Resveratrol; Sorafenib | 2021 |
2 other study(ies) available for resveratrol and sorafenib
| Article | Year |
|---|---|
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPĪµ and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes | 2016 |
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome | 2016 |